Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
FDA reviews ReGen clearance at March panel: Agency's Orthopaedic and Rehabilitation Devices advisory panel will discuss the controversial 510(k) clearance of ReGen Biologics' Collagen Scaffold device, previously Menaflex, at a March 23 meeting. Last year, FDA launched an unprecedented re-assessment of its review of the knee repair device, 510(k)-cleared in December 2008, because of concerns that internal and political pressures may have hijacked the review process. The agency unearthed serious shortcomings in the integrity of the process, and FDA vowed to conduct a separate review of the Menaflex clearance to determine whether the data support 510(k) clearance, or whether the device should be up-classified to a Class III PMA device (1"The Gray Sheet" Sept. 28, 2009)
You may also be interested in...
Internal FDA Menaflex Investigation Finds Serious Process Deviations
An internal evaluation of FDA's handling of the controversial 510(k) clearance of a knee implant unearthed serious shortcomings in the integrity of the agency's review process, FDA said Sept. 24
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.